Healthy Longevity ScienceExplore the questions behind healthy longevity. Understand the evidence, its possibilities and its limits.
10 articles
PeptidesPeptides can be effective medicines because they act on specific biological systems. Insulin and semaglutide show what that can achieve; research into repair and healthy aging asks different, often much earlier questions. Understanding the exact molecule, the human evidence, and the relevant regulatory decision makes it easier to judge what a peptide claim means for patients.
PeptidesPeptide regulation shapes how products can be made, supplied, and promoted. The key is identifying the decision: approval of a medicine, a change in pharmacy preparation rules, or an advisory recommendation. The July 2026 US peptide review concerned particular ingredients and uses; it did not itself approve treatments. This guide explains what those distinctions mean for patients and why European and Czech rules apply separately.
PeptidesBPC-157 affects processes involved in repair in laboratory and animal studies. Human studies, however, have not reliably shown that it helps injuries heal or established its risks. Small clinical reports and a larger analysis of medical records describe mixed experiences; a registered hamstring trial has no posted results. Understanding what each study measured helps distinguish a promising research idea from a demonstrated treatment.
PeptidesThymosin beta-4 has inspired research on tissue repair, including studies of eye drops and a distinct injectable drug candidate. Those results do not establish that the shorter peptide sold as TB-500 heals injuries. The useful question is which molecule was tested, in which preparation, and for which condition. Following those details reveals both a reason for continued research and the limits of today’s treatment claims.
PeptidesMOTS-c is a small peptide, a short chain of amino acids, that helps researchers study how cells respond to energy demands. Human exercise studies and mouse treatment experiments make it an interesting candidate for further research. They have not established that taking MOTS-c reproduces exercise, produces lasting weight loss, or slows human aging. It matters whether a study measured the body’s own peptide, gave the peptide as a treatment, or tested a deliberately modified version. Each answers a different question.
PeptidesEpitalon can affect the systems that maintain telomeres, the protective structures at chromosome ends, in laboratory cells. Limited human reports have explored other biological effects. That is a starting point for research, not evidence that taking the peptide adds healthy years to life. The often-cited long-term survival study tested a different preparation, Epithalamin. Distinguishing the two preparations, and a laboratory marker from a health benefit, helps put longevity and sleep claims in perspective.
PeptidesGrowth hormone secretagogues are drugs that stimulate the release of growth hormone. They can raise growth hormone and insulin-like growth factor 1 (IGF-1), and some increase lean body mass, which includes muscle and other tissues. The harder question is whether people become stronger, think more clearly, or remain independent for longer. Human trials give mixed answers, with some encouraging findings and meaningful harms. Tesamorelin has a specific US-approved use, but these studies have not established hormone stimulation as a treatment for normal aging.
PeptidesThymosin alpha-1 has been studied in people with serious infections and in older adults receiving vaccines. Some studies found changes in immune responses, but a large trial in sepsis—a life-threatening response to infection—found no clear survival benefit. A registered use for hepatitis, or liver inflammation, in Singapore also does not establish a healthy-aging benefit. The useful question is which immune response changes, in whom, and whether that change helps people stay well.
Removing certain damaged cells may help aging tissues function better. FOXO4-DRI helped test that idea in cells and mice, but human longevity benefits remain unproven. Cleara Biotech, a LongevityTech.fund portfolio company, is developing distinct candidates focused on cancer. The research shows why targeting the right cells could matter—and what it takes to turn that insight into a tested medicine.
PeptidesLL-37 is a natural part of the body’s defenses, but making it—or a molecule inspired by it—into a useful medicine is a separate challenge. Human LL-37 studies have produced mixed results, including trials with no overall benefit. Maxwell Biosciences is developing chemically different, peptide-inspired molecules called peptoids. They have promising laboratory and animal findings, but their benefit to patients remains unproven. Neither research path establishes a treatment for healthy aging.